Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab + Isatuximab + Bortezomib + Lenalidomide in Ultra-High-Risk Multiple Myeloma
NCT07789522Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2026
- Primary completion
- Oct 2027
01
Overview
A Phase 2 trial of elranatamab in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07789522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07789522.